diazoxide and exendin (9-39)

diazoxide has been researched along with exendin (9-39) in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (33.33)18.2507
2000's1 (33.33)29.6817
2010's0 (0.00)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Delmeire, D; Drucker, DJ; Flamez, D; Gilon, P; Henquin, JC; Moens, K; Schuit, F; Scrocchi, LA; Van Breusegem, A1
D'Amico, E; Di Mario, U; Hui, H; Khoury, N; Perfetti, R1
Axelrod, F; Chai, J; Challocombe, Z; Chan, KY; De León, DD; Haas, N; Han, Z; Holliday, C; Hu, CF; Juliana, CA; Lujan Hernandez, AG; Peterson, SM; Sato, AK; Stafford, R; Wang, L; Yuan, TZ1

Other Studies

3 other study(ies) available for diazoxide and exendin (9-39)

ArticleYear
Altered cAMP and Ca2+ signaling in mouse pancreatic islets with glucagon-like peptide-1 receptor null phenotype.
    Diabetes, 1999, Volume: 48, Issue:10

    Topics: Acetylcholine; Animals; Calcium; Cells, Cultured; Cyclic AMP; Diazoxide; Female; Glucagon-Like Peptide-1 Receptor; Glucose; Islets of Langerhans; Male; Mice; Mice, Knockout; Peptide Fragments; Phenotype; Receptors, Glucagon; Signal Transduction

1999
Pancreatic beta-cells expressing GLP-1 are resistant to the toxic effects of immunosuppressive drugs.
    Journal of molecular endocrinology, 2005, Volume: 34, Issue:2

    Topics: Animals; Antihypertensive Agents; Apoptosis; Apoptosis Regulatory Proteins; Carrier Proteins; Caspase 3; Caspases; Cell Line, Tumor; Cell Survival; Diazoxide; DNA Fragmentation; Dose-Response Relationship, Drug; Glucagon; Glucagon-Like Peptide 1; Glucose; Humans; Immunosuppressive Agents; Insulin; Insulin Secretion; Intracellular Signaling Peptides and Proteins; Islets of Langerhans; Mice; Mitochondrial Proteins; Peptide Fragments; Protein Precursors; Proto-Oncogene Proteins c-bcl-2

2005
Optimization of a Glucagon-Like Peptide 1 Receptor Antagonist Antibody for Treatment of Hyperinsulinism.
    Diabetes, 2023, 09-01, Volume: 72, Issue:9

    Topics: Animals; Antibodies; Blood Glucose; Congenital Hyperinsulinism; Diazoxide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Hyperinsulinism; Mice; Mutation; Sulfonylurea Receptors

2023